SILA trades 0.1% below Wall Street's consensus target of $30.33.
Last 12 months price action with 12-month analyst target path
The base valuation assumes SILA achieves its forward estimates and maintains a stable P/E multiple of 46.6x. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 28, 2026, Sila Realty Trust, Inc. (SILA) has a Wall Street consensus price target of $30.33, based on estimates from 4 covering analysts. With the stock currently trading at $30.31, this represents a potential upside of +0.1%. The company has a market capitalization of $1.67B.
Analyst price targets range from a low of $30.00 to a high of $31.00, representing a 3% spread in expectations. The median target of $30.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, SILA trades at a trailing P/E of 50.5x and forward P/E of 46.6x. Analysts expect EPS to grow -4.3% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $32.10, with bear and bull scenarios of $20.22 and $42.29 respectively. Model confidence stands at 40/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
CHCTCommunity Healthcare Trust Incorporated | $524M | $18.33 | $18.50 | +0.9% | Hold | 39.0x | 16 |
GMREGlobal Medical REIT Inc. | $94M | $35.74 | $40.00 | +11.9% | Buy | 595.7x | 22 |
MDRRMedalist Diversified REIT, Inc. | $14M | $11.22 | — | — | — | — | — |
HRHealthcare Realty Trust Incorporated | $7.2B | $20.50 | $21.83 | +6.5% | Hold | — | 30 |
OHIOmega Healthcare Investors, Inc. | $14.3B | $48.06 | $50.43 | +4.9% | Hold | 24.2x | 28 |
SBRASabra Health Care REIT, Inc. | $4.9B | $19.54 | $21.00 | +7.5% | Hold | 29.0x | 29 |
LTCLTC Properties, Inc. | $2.0B | $38.46 | $36.00 | -6.4% | Hold | 20.5x | 22 |
CTRECareTrust REIT, Inc. | $9.6B | $40.83 | $44.25 | +8.4% | Buy | 27.4x | 19 |
NHINational Health Investors, Inc. | $3.8B | $77.55 | $82.83 | +6.8% | Hold | 21.8x | 18 |
WELLWelltower Inc. | $159.2B | $227.21 | $237.80 | +4.7% | Buy | 78.4x | 35 |
Quick answers to the most common questions about buying SILA stock.
The consensus price target for SILA is $30.33, close to the current price of $30.31 (0.1% implied move). Based on 4 analyst estimates, the stock appears fairly valued near current levels.
SILA has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is mixed, with 2 Hold ratings making up the largest segment. The consensus 12-month price target of $30.33 implies 0.1% upside from current levels.
At a forward P/E of 46.6308x, SILA trades at a premium valuation. The consensus price target of $30.33 (0.1% upside) suggests analysts may view current valuations as stretched.
The most bullish Wall Street analyst has a price target of $31 for SILA, while the most conservative target is $30. The consensus of $30.33 represents the median expectation. Our quantitative valuation model projects a bull case target of $42 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
SILA is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month SILA stock forecast based on 4 Wall Street analysts shows a consensus price target of $30.33, with estimates ranging from $30 (bear case) to $31 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $32, with bear/bull scenarios of $20/$42.
Our quantitative valuation model calculates SILA's fair value at $32 (base case), with a bear case of $20 and bull case of $42. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 40/100.
SILA trades at a forward P/E ratio of 46.6x based on next-twelve-months earnings estimates compared to a trailing P/E of 50.5x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
SILA appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $30.33 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
SILA analyst price targets range from $30 to $31, a 3% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $30.33 consensus represents the middle ground. Our model's $20-$42 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.